Servier's U.S. CEO discusses FDA approval of Voranigo, a targeted therapy for a common type of brain cancer
David Lee describes the glioma brain cancer population this IHD1/2 targeting therapy is for, Servier's experience commercializing cancer medicines, and how he thinks about deals going forward.